Home

SAB Biotherapeutics, Inc. - Common Stock (SABS)

1.1900
-0.0600 (-4.80%)
NASDAQ · Last Trade: Apr 3rd, 3:52 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Why Is SAB BIO Stock Trading Lower On Tuesday?benzinga.com
SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.
Via Benzinga · January 28, 2025
Gold Gains 1%; Boeing Shares Rise Following Q4 Resultsbenzinga.com
Via Benzinga · January 28, 2025
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Resultsmarkets/com
Via Benzinga · January 28, 2025
Dow Gains Over 50 Points; General Motors Posts Upbeat Earningsbenzinga.com
Via Benzinga · January 28, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · October 18, 2024
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024investorplace.com
SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 20, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · June 19, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · June 18, 2024
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · May 23, 2024
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024investorplace.com
SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 21, 2024
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Shares of Applied Therapeutics, Inc.
Via Benzinga · January 5, 2024
Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesdaybenzinga.com
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via Benzinga · January 3, 2024
VerifyMe And 3 Other Stocks Under $2 Insiders Are Buyingbenzinga.com
The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · December 1, 2023
EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australiabenzinga.com
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia. 
Via Benzinga · November 29, 2023
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · November 16, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 24, 2023
Nasdaq Falls 100 Points; AT&T Posts Upbeat Earningsbenzinga.com
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 33,520.17 while the NASDAQ fell 0.75% to 13,214.04. The S&P 500 also fell, dropping, 0.62% to 4,287.95.
Via Benzinga · October 19, 2023
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · October 19, 2023
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionbenzinga.com
Gainers
Via Benzinga · October 19, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 19, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 2, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023benzinga.com
Via Benzinga · October 5, 2023
EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidatebenzinga.com
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.
Via Benzinga · October 2, 2023
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via Benzinga · September 29, 2023